Annals of Hematology· 2026Q2
National trends and inpatient outcomes of venous thromboembolism in hospitalized acute leukemia: a propensity-score weighted analysis, 2016–2022
- 0citations
- Q2SCImago
- 2026year
Short summary
Venous thromboembolism (VTE) occurred in 4.6% of acute leukemia hospitalizations (n=191,640 weighted) between 2016-2022, with prevalence significantly increasing to 5.3% by 2021.
AI-generated from the title and abstract; the full text is not read.
Key points
- VTE prevalence in acute leukemia hospitalizations increased from 2016-2022 (p=0.032), peaking at 5.3% in 2021.
- Among 191,640 weighted hospitalizations, 4.6% had VTE.
- VTE was independently associated with higher in-hospital mortality (aOR 1.478), longer LOS (8.41 days), and greater hospital charges ($127,633).
- VTE was linked to lower odds of blood product transfusion (aOR 0.842).
AI-generated from the title and abstract; the full text is not read.
Abstract
Venous thromboembolism (VTE) is a recognized complication of acute leukemia, yet its national prevalence, temporal trends, and associations with inpatient outcomes remain poorly characterized. We aimed to provide a contemporary, nationally representative analysis of VTE burden and outcomes among hospitalized adults with acute leukemia. We conducted a retrospective analysis of the National Inpatient Sample (NIS, 2016–2022). Adult hospitalizations with a principal diagnosis of acute leukemia were identified using ICD-10-CM codes. VTE was the primary exposure. The primary outcome was any blood product transfusion. Transfusion was selected as the primary outcome because acute leukemia is characterized by a complex balance between thrombosis, thrombocytopenia, bleeding risk, and supportive transfusion requirements, making transfusion use a clinically relevant marker of this competing thrombohemorrhagic burden; secondary outcomes included in-hospital mortality, length of stay (LOS), and inflation-adjusted hospital charges. Multivariable regression models accounted for the complex NIS survey design. Temporal trends were assessed using predictive margins. Propensity-score weighted (PSW) sensitivity analyses using ATT weights evaluated the robustness of primary findings. Among 191,640 weighted hospitalizations, 8,880 (4.6%) had VTE. Adjusted VTE prevalence increased significantly between 2016 and 2022 ( p = 0.032), and peaked at 5.3% in 2021. After multivariable adjustment, VTE was independently associated with lower odds of blood product transfusion (aOR 0.842; 95% CI, 0.761–0.932; p = 0.001), higher in-hospital mortality (aOR 1.478; 95% CI, 1.276–1.711; p < 0.001), longer LOS (β, 8.41 days; p < 0.001), and higher hospital charges (β, $127,633; p < 0.001). All associations remained stable in PSW sensitivity analyses. VTE was identified in approximately 1 in 22 hospitalizations of adults with acute leukemia, and its prevalence rose significantly over the study period. VTE was independently associated with higher mortality, prolonged hospitalization, and greater hospital charges. The paradoxical inverse association with transfusion may reflect unmeasured disease severity and competing thrombohemorrhagic risks.
The authors' abstract, as published at the source. Annals of Hematology, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Internal Medicine
Internal MedicineMedicine